Terrisse, Safae
Derosa, Lisa
Iebba, Valerio
Ghiringhelli, François http://orcid.org/0000-0002-5465-8305
Vaz-Luis, Ines
Kroemer, Guido http://orcid.org/0000-0002-9334-4405
Fidelle, Marine
Christodoulidis, Stergios http://orcid.org/0000-0002-8773-1070
Segata, Nicola http://orcid.org/0000-0002-1583-5794
Thomas, Andrew Maltez http://orcid.org/0000-0001-5789-3354
Martin, Anne-Laure
Sirven, Aude
Everhard, Sibille
Aprahamian, Fanny
Nirmalathasan, Nitharsshini
Aarnoutse, Romy http://orcid.org/0000-0002-8713-9747
Smidt, Marjolein
Ziemons, Janine http://orcid.org/0000-0002-4559-5488
Caldas, Carlos http://orcid.org/0000-0003-3547-1489
Loibl, Sibylle
Denkert, Carsten
Durand, Sylvere
Iglesias, Claudia
Pietrantonio, Filippo
Routy, Bertrand
André, Fabrice
Pasolli, Edoardo
Delaloge, Suzette
Zitvogel, Laurence http://orcid.org/0000-0003-1596-0998
Article History
Received: 18 January 2021
Revised: 5 April 2021
Accepted: 12 April 2021
First Online: 7 May 2021
Compliance with ethical standards
:
: The authors LZ, GK declare being founders of everImmune. FP declares grants and other from Abbvie, grants and other from Amgen, grants and other from Celgene, grants and other from Novartis, grants and other from Roche, other from Seattle Genetics, other from PriME/Medscape, personal fees from Chugai, grants and other from Daiichi-Sankyo, other from Lilly, other from Samsung, other from BMS, other from Puma, other from MSD, grants from Immunomedics, grants and other from AstraZeneca, grants and other from Pfizer, other from Pierre Fabre and other from Merck outside the submitted work; In addition, SL has a patent EP14153692.0 pending. CD declares personal fees from Roche, Amgen, Merck-Serono, Bayer, Servier, Sanofi and research Grants from BMS. SL declares honoraria: Novartis, Roche, consulting: MSD oncology, Daiitchi Sankyo, molecular health, ownership nterest: Myriad, Reserche funding: Myriad genetics. Intellectual property: VMScope digital pathology software Recipient, Patent application: EP18209672—cancer immunotherapy, Patent application EP20150702464—therapy response, Patent application EP20150702464—therapy response. The other authors have no conflicts of interest to declare.